JPWO2020035816A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020035816A5 JPWO2020035816A5 JP2021507760A JP2021507760A JPWO2020035816A5 JP WO2020035816 A5 JPWO2020035816 A5 JP WO2020035816A5 JP 2021507760 A JP2021507760 A JP 2021507760A JP 2021507760 A JP2021507760 A JP 2021507760A JP WO2020035816 A5 JPWO2020035816 A5 JP WO2020035816A5
- Authority
- JP
- Japan
- Prior art keywords
- agent
- pharmaceutical composition
- peg
- formula
- agent according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 77
- 238000000034 method Methods 0.000 claims description 60
- 239000008194 pharmaceutical composition Substances 0.000 claims description 40
- 239000000412 dendrimer Substances 0.000 claims description 14
- 229920000736 dendritic polymer Polymers 0.000 claims description 14
- 229960000583 acetic acid Drugs 0.000 claims description 12
- 206010028980 Neoplasm Diseases 0.000 claims description 10
- 201000011510 cancer Diseases 0.000 claims description 10
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- 239000013543 active substance Substances 0.000 claims description 6
- 239000012535 impurity Substances 0.000 claims description 6
- 229940126062 Compound A Drugs 0.000 claims description 4
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
- 239000011859 microparticle Substances 0.000 claims description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
- 239000000243 solution Substances 0.000 claims description 4
- 239000008351 acetate buffer Substances 0.000 claims description 2
- 239000007979 citrate buffer Substances 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000012362 glacial acetic acid Substances 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims 57
- 125000003277 amino group Chemical group 0.000 claims 4
- 239000000126 substance Substances 0.000 description 21
- 150000001412 amines Chemical group 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862719314P | 2018-08-17 | 2018-08-17 | |
| US62/719,314 | 2018-08-17 | ||
| PCT/IB2019/056926 WO2020035816A1 (en) | 2018-08-17 | 2019-08-15 | Conjugates for use in methods of treating cancer |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021534162A JP2021534162A (ja) | 2021-12-09 |
| JP2021534162A5 JP2021534162A5 (https=) | 2022-08-22 |
| JPWO2020035816A5 true JPWO2020035816A5 (https=) | 2022-08-22 |
| JP7506659B2 JP7506659B2 (ja) | 2024-06-26 |
Family
ID=68104689
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021507760A Active JP7506659B2 (ja) | 2018-08-17 | 2019-08-15 | 癌を処置する方法に用いられるコンジュゲート |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20220273807A1 (https=) |
| EP (1) | EP3836973A1 (https=) |
| JP (1) | JP7506659B2 (https=) |
| KR (1) | KR20210047301A (https=) |
| CN (1) | CN112584869A (https=) |
| AU (1) | AU2019321091C1 (https=) |
| BR (1) | BR112021002147A2 (https=) |
| CA (1) | CA3108638A1 (https=) |
| EA (1) | EA202190457A1 (https=) |
| IL (1) | IL280830A (https=) |
| MX (1) | MX2021001832A (https=) |
| SG (1) | SG11202101395XA (https=) |
| TW (1) | TWI831817B (https=) |
| WO (1) | WO2020035816A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI773730B (zh) * | 2017-02-22 | 2022-08-11 | 瑞典商阿斯特捷利康公司 | 治療性樹枝狀聚合物 |
| TWI856967B (zh) * | 2018-08-17 | 2024-10-01 | 瑞典商阿斯特捷利康公司 | 樹枝狀體配製物 |
| US20230250077A1 (en) * | 2020-07-10 | 2023-08-10 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Sulfonylbenzamide derivative and conjugate thereof, preparation method therefor and use thereof |
| US20230263900A1 (en) * | 2020-08-31 | 2023-08-24 | Starpharma Pty Ltd. | Dendrimer-drug conjugate |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI535712B (zh) * | 2010-08-06 | 2016-06-01 | 阿斯特捷利康公司 | 化合物 |
| BR112013031556B1 (pt) * | 2011-06-06 | 2022-03-29 | Starpharma Pty Ltd | Macromoléculas, uso das mesmas para tratar ou suprimir o crescimento de um câncer e composições farmacêuticas |
| WO2015035446A1 (en) * | 2013-09-10 | 2015-03-19 | Starpharma Pty Ltd | Macromolecules of dendrimer-platinum conjugates |
| TWI773730B (zh) * | 2017-02-22 | 2022-08-11 | 瑞典商阿斯特捷利康公司 | 治療性樹枝狀聚合物 |
-
2019
- 2019-08-08 TW TW108128356A patent/TWI831817B/zh not_active IP Right Cessation
- 2019-08-15 EA EA202190457A patent/EA202190457A1/ru unknown
- 2019-08-15 CN CN201980053352.4A patent/CN112584869A/zh active Pending
- 2019-08-15 SG SG11202101395XA patent/SG11202101395XA/en unknown
- 2019-08-15 CA CA3108638A patent/CA3108638A1/en active Pending
- 2019-08-15 AU AU2019321091A patent/AU2019321091C1/en not_active Ceased
- 2019-08-15 MX MX2021001832A patent/MX2021001832A/es unknown
- 2019-08-15 BR BR112021002147-7A patent/BR112021002147A2/pt not_active Application Discontinuation
- 2019-08-15 WO PCT/IB2019/056926 patent/WO2020035816A1/en not_active Ceased
- 2019-08-15 EP EP19779977.8A patent/EP3836973A1/en active Pending
- 2019-08-15 JP JP2021507760A patent/JP7506659B2/ja active Active
- 2019-08-15 KR KR1020217004509A patent/KR20210047301A/ko not_active Ceased
- 2019-08-15 US US17/268,633 patent/US20220273807A1/en not_active Abandoned
-
2021
- 2021-02-11 IL IL280830A patent/IL280830A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2004261165C1 (en) | Composition of a VEGF antagonist and an anti-proliferative agent and its use for the treatment of cancer | |
| US8466127B2 (en) | Pegylated and fatty acid grafted chitosan oligosaccharide, synthesis method and application for drug delivery system | |
| EP2029120B1 (en) | Nanoparticles containing three various ligands for providing immune responses against infectious agents | |
| JPWO2020061295A5 (https=) | ||
| JP2021534162A5 (https=) | ||
| CN115703713B (zh) | 阳离子脂质化合物 | |
| US20250057975A1 (en) | Small polymeric carriers for delivery of agents | |
| CN115710192B (zh) | 阳离子脂质化合物 | |
| US20100104533A1 (en) | Early intervention of viral infection with immune activators | |
| WO1990001322A1 (en) | Novel method of administering aspirin and dosage forms containing same | |
| CN114409554A (zh) | 一种新型阳离子脂质化合物及其组合物和用途 | |
| CN116332879A (zh) | 一种卡巴他赛前药抗肿瘤制剂 | |
| CN111793147A (zh) | 改性壳聚糖、双响应纳米载体药及其制备方法和应用 | |
| CN114377141B (zh) | 一种药物递送载体及其抗肿瘤应用 | |
| CN120152987A (zh) | 呼吸道合胞病毒rna疫苗接种 | |
| JPWO2020035816A5 (https=) | ||
| US20100261739A1 (en) | Method of Treating Non-Small Cell Lung Cancer | |
| US20230404933A1 (en) | NON-CATIONIC SOFT POLYPHENOL NANOCAPSULES FOR EFFECTIVE SYSTEMIC DELIVERY OF SMALL INTERFERING RNA (siRNA) FOR CANCER TREATMENT | |
| CN120204135A (zh) | 靶向卵巢的mRNA脂质体纳米颗粒、制备方法、药物复合物、靶向递送系统及应用 | |
| US20140135357A1 (en) | Dose regime for camptothecin derivatives | |
| CN115710191B (zh) | 阳离子脂质化合物 | |
| US20090175947A1 (en) | Pharmaceutical composition for injectional particularly targeted local administration | |
| CN115710193B (zh) | 阳离子脂质化合物 | |
| US20100087399A1 (en) | Use of 9-oxoacridine-10-acetic acid, salts and esters thereof in combination therapy of ovarian cancer | |
| Zhao et al. | Pharmacokinetic research progress of anti-tumor drugs targeting for pulmonary administration |